<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378414</url>
  </required_header>
  <id_info>
    <org_study_id>SCLnow-XY-03</org_study_id>
    <nct_id>NCT03378414</nct_id>
  </id_info>
  <brief_title>Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia</brief_title>
  <official_title>A Clinical Research on the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sclnow Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sclnow Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is verify the safety and efficacy of Human Umbilical Cord
      Mesenchymal Stem Cells (UC-MSC) therapy for patients with Spinocerebellar Ataxia, and in
      addition, explore the possible mechanisms of UC-MSC therapy in Spinocerebellar Ataxia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a random, open label, and parallel controled experiment. 45 patients are selected and
      sign consent forms, then divided into three groups. Doctors collect the basic information of
      patient (including age,height, mental condition, vital sign, history of disease,
      pharmaco-history, genotype test, and so on.) All patients receive laboratory and image
      examination as baseline. Then, they will give cell treatment based on the clinical protocol.
      Doctors have follow-up visit on 1, 2, 3, 6, and 12 months after treatment, and do efficacy
      evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for the assessment anf rating of ataxia (SARA)</measure>
    <time_frame>12 months</time_frame>
    <description>Based on SARA score to calculate treatment efficacy. The equation is as follow, Efficacy = (patients who accepted treatment are effective/patients who accepted treatment)* 100% Effective: after 12 months, score of patient decrease 1 point or more; Ineffective: after 12 months, score decrease less than 1 point or increase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Image examinations</measure>
    <time_frame>12 months</time_frame>
    <description>MRI plain scan of brain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inventory of Non-Ataxia Symptoms (INAS) score</measure>
    <time_frame>12 months</time_frame>
    <description>Using Inventory of Non-Ataxia Symptoms (INAS) score to determine the presence and severity of non-ataxia signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid (csf) routine</measure>
    <time_frame>12 months</time_frame>
    <description>Patients is observed by professionals, compare the changes of each observation point and baseline. Baseline is the data acquire from patients before stem cells treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Spinocerebellar Ataxia Type 1</condition>
  <condition>Spinocerebellar Ataxia Type 2</condition>
  <condition>Spinocerebellar Ataxia Type 3</condition>
  <condition>Spinocerebellar Ataxia Type 6</condition>
  <arm_group>
    <arm_group_label>Intravenous infusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical cord mesenchymal stem cells (SCLnow 19#)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Umbilical cord mesenchymal stem cells (SCLnow 19#)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control groups</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravenous infusion</intervention_name>
    <description>Intravenous infusion of mesenchymal stem cells: 2 * 10^7 cells (30ml)</description>
    <arm_group_label>Intravenous infusion group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrathecal injection</intervention_name>
    <description>Intrathecal injection of mesenchymal stem cells: 2 * 10^7 cells (1ml)</description>
    <arm_group_label>Intrathecal injection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>umbilical cord mesenchymal stem cell</intervention_name>
    <description>Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure</description>
    <arm_group_label>Intravenous infusion group</arm_group_label>
    <arm_group_label>Intrathecal injection group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and genomic test diagnoses as spinocerebellar ataxias (SCA) (include SCA 1,
             SCA 2, SCA 3, SCA 6), SARA (Scale for Assessment and Rating of Ataxia) score is 2-5,
             can complete 8-meter walking test（8MW）

          -  Do not receive stem cells treatment in 6 months

          -  Participants sign the consent form based on the experiment process and statement

        Exclusion Criteria:

          -  Cardiac, renal, hepatic insufficiency; total bilirubin is 1.5 times higher than normal
             value, aspartate transaminase（AST）or alanine aminotransferase（ALT）is 2.5 times higher
             than normal value

          -  Hemogram: total white blood cells &lt;3.0 * 10^9 cells/L, blood platelet &lt;75 * 10^9/L,
             hemoglobin &lt;100g/L

          -  pneumonia, or severe infection

          -  With severe allergic history

          -  Brain organic disorder, like brain tumor

          -  Serum with HIV, syphilis antibody positive

          -  Severe mental disease, cognitive disorder patients

          -  Other severe system or organ organic disease

          -  Pregnant, breast feeding, or planning pregnant women

          -  Participate other clinical experiments in 3 months

          -  With some other conditions that doctor propose not to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Jiang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Guo</last_name>
    <phone>861064368977</phone>
    <email>georgeguo@sclnow.com</email>
  </overall_contact>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinocerebellar Ataxia,Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

